BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31577942)

  • 1. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
    Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
    Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
    Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
    Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.
    Xie CM; Tan M; Lin XT; Wu D; Jiang Y; Tan Y; Li H; Ma Y; Xiong X; Sun Y
    Cell Rep; 2019 Mar; 26(11):3037-3050.e4. PubMed ID: 30865892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective.
    Kwon JJ; Hahn WC
    Mol Cell Biol; 2021 Mar; 41(4):. PubMed ID: 33526449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK in cancer and cancer therapy.
    Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
    Boned Del Río I; Young LC; Sari S; Jones GG; Ringham-Terry B; Hartig N; Rejnowicz E; Lei W; Bhamra A; Surinova S; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13330-13339. PubMed ID: 31213532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.
    Wang B; Krall EB; Aguirre AJ; Kim M; Widlund HR; Doshi MB; Sicinska E; Sulahian R; Goodale A; Cowley GS; Piccioni F; Doench JG; Root DE; Hahn WC
    Cell Rep; 2017 Feb; 18(6):1543-1557. PubMed ID: 28178529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on Accessory Proteins: RTK-RAS-MAPK Modulators as New Therapeutic Targets.
    Pudewell S; Ahmadian MR
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
    Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
    Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural cell adhesion molecule-stimulated neurite outgrowth depends on activation of protein kinase C and the Ras-mitogen-activated protein kinase pathway.
    Kolkova K; Novitskaya V; Pedersen N; Berezin V; Bock E
    J Neurosci; 2000 Mar; 20(6):2238-46. PubMed ID: 10704499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the MRAS-SHOC2-PP1C phosphatase complex.
    Hauseman ZJ; Fodor M; Dhembi A; Viscomi J; Egli D; Bleu M; Katz S; Park E; Jang DM; Porter KA; Meili F; Guo H; Kerr G; Mollé S; Velez-Vega C; Beyer KS; Galli GG; Maira SM; Stams T; Clark K; Eck MJ; Tordella L; Thoma CR; King DA
    Nature; 2022 Sep; 609(7926):416-423. PubMed ID: 35830882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
    Rodriguez-Viciana P; Oses-Prieto J; Burlingame A; Fried M; McCormick F
    Mol Cell; 2006 Apr; 22(2):217-30. PubMed ID: 16630891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
    Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
    Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf.
    Matsunaga-Udagawa R; Fujita Y; Yoshiki S; Terai K; Kamioka Y; Kiyokawa E; Yugi K; Aoki K; Matsuda M
    J Biol Chem; 2010 Mar; 285(10):7818-26. PubMed ID: 20051520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.